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Letter to the Editor
Single-dose rifampicin and BCG to prevent
leprosy
Dear Editor,
The MALTALEP trial compared the efﬁcacy of bacillus Calmette–
Guérin (BCG) vaccination followed by single-dose rifampicin (SDR)
with BCG vaccination alone in preventing leprosy in household
contacts and next-door neighbours of newly diagnosed leprosy
patients in Bangladesh (Richardus et al., 2019). It was a large, well
designed cluster randomised controlled trial (RCT) and 14,988
contacts of 1552 new leprosy patients were randomised to receive
either BCG alone (7378) or BCG followed by SDR (7609) 8–12 weeks
later. Participants were followed for 2 years.
The primary outcome of the RCT recorded in the Netherlands
Trial Register (NTR3087) and reported in the peer-reviewed
protocol was “New cases of leprosy among the contacts of index
cases” and “ . . . the number of new leprosy patients emerging
from the contact groups” respectively (Richardus et al., 2013).
There were no signiﬁcant differences between the proportions of
contacts who developed leprosy following the interventions at one
or two years. This is an important negative ﬁnding and in keeping
with the ﬁndings of the COLEP RCT of SDR (Moet et al., 2008). The
COLEP trial identiﬁed that the short-term beneﬁts of SDR were only
signiﬁcant in more distant contacts of index cases.
A secondary data analysis was planned to “deﬁne special groups
at risk for developing leprosy” and “No signiﬁcant differences of
interest were found” (Richardus et al., 2013). The authors discuss
the non-signiﬁcant 42% reduction in the number of new cases of
paucibacillary leprosy in those who received SDR after one year.
We were surprised that the signiﬁcant number of individuals who
developed multibacillary (MB) leprosy in the SDR group by 2 years
was not similarly discussed. The odds of having developed MB
leprosy at the two year follow up point were 3.68 (95% CI: 1.03–
13.21) in the group randomised to receive BCG and SDR compared
to BCG alone. Table 6 states that only one of 11 new cases of MB
leprosy diagnosed after completion of the intervention was slit-
skin smear positive. The clinical relevance of the increased
numbers of MB patients should be discussed including information
about nerve function impairment. The COLEP trial did not show
any signiﬁcant difference in the amount of MB disease between the
SDR and placebo groups during two or four years of follow up
(Moet et al., 2008).
The MALTALEP study shows that SDR after BCG does not have a
signiﬁcant protective effect against leprosy in household and next-
door neighbour contacts compared to BCG alone. This replicates
the ﬁnding from the larger COLEP study. Data from the BCG arm of
the current study were compared with the placebo arm of the
COLEP study to infer that the protective effect of BCG is doubtful in
Bangladesh.
We agree with Richardus et al. that the current evidence does
not support the use of BCG followed by SDR for the contacts of
leprosy patients (Richardus et al., 2019) and with WHO that the
evidence for BCG alone is conﬂicting with no evidence of beneﬁt
(2018a).
The incomplete understanding of the transmission of Mycobac-
terium leprae and dev elopment of disease hamper the discovery of
an effective strategy for prevention. The administration of SDR to
contacts of individuals diagnosed with leprosy is recommended by
WHO without providing criteria to determine who is a contact
(2018b).
The evidence for SDR as a strategy to prevent leprosy or achieve
the target of zero transmission of M. leprae remains limited.
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